First Patient In

At least a dozen first-patient-in milestones were announced between 30 September and 7 October, led by the first in vivo Prime Editing trial in Wilson disease and a new wave of dual-payload and bispecific ADCs out of China. Australia again proved the go-to launchpad for overseas sponsors, while Europe saw two companies, Orion and CHARM, become clinical-stage in biologics and AI-designed drugs. Each item below links to the full release.